SELLAS Life Sciences Group, Inc. (SLS) income statement
NASDAQ · Healthcare · Biotechnology · 13 employees · CEO Angelos Stergiou
- Price
- $14.69 +2.0%
- Market cap
- $2.78B
- Enterprise value
- $2.65B Data as of 2026-11-21
- Last report
- Q3 '26 filed 2026-11-12
- Next report
- 2027-03-25 EPS est. -$0.05
Income statement
| Income statement | Trend | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | $5.1M | $5.11M | $5.19M | $4.36M | $4.44M | $3.21M | $3.87M | $4.22M | $4.73M | $5.13M | $6.27M | $7.03M | |
| General & administrative | $3.08M | $4.53M | $2.44M | $2.97M | $2.48M | $2.86M | $3M | $2.87M | $3.53M | $4.12M | $4.36M | $4.28M | |
| Operating expenses | $8.18M | $9.65M | $7.62M | $7.33M | $6.92M | $6.06M | $6.87M | $7.08M | $8.26M | $9.25M | $10.6M | $11.3M | |
| Operating income | -$8.18M | -$9.65M | -$7.62M | -$7.33M | -$6.92M | -$6.06M | -$6.87M | -$7.08M | -$8.26M | -$9.25M | -$10.6M | -$11.3M | |
| Interest income | $41K | $79K | $151K | $221K | $181K | $250K | $272K | $292K | $597K | $845K | $1.02M | $1.22M | |
| Other non-operating income (gains on investments, FX ...) | -$41K | -$79K | -$151K | -$221K | -$181K | -$250K | -$272K | -$292K | -$597K | -$845K | -$1.02M | -$1.22M | |
| Total non-operating income | $41K | $79K | $151K | $221K | $181K | $250K | $272K | $292K | $597K | $845K | $1.02M | $1.22M | |
| Income before tax | -$8.14M | -$9.57M | -$7.47M | -$7.11M | -$6.74M | -$5.81M | -$6.6M | -$6.79M | -$7.66M | -$8.41M | -$9.61M | -$10.1M | |
| Net income | -$8.14M | -$9.57M | -$7.47M | -$7.11M | -$6.74M | -$5.81M | -$6.6M | -$6.79M | -$7.66M | -$8.41M | -$9.61M | -$10.1M | |
| EPS (basic) | -$0.26 | -$0.21 | -$0.13 | -$0.10 | -$0.09 | -$0.07 | -$0.07 | -$0.06 | -$0.05 | -$0.05 | -$0.05 | -$0.05 | |
| EPS (diluted) | -$0.26 | -$0.21 | -$0.13 | -$0.10 | -$0.09 | -$0.07 | -$0.07 | -$0.06 | -$0.05 | -$0.05 | -$0.05 | -$0.05 | |
| Shares (basic, weighted) | 30.8M | 44.8M | 57.5M | 68.3M | 74M | 87.8M | 94.3M | 108M | 153M | 172M | 189M | 202M | |
| Shares (diluted, weighted) | 30.8M | 44.8M | 57.6M | 68.3M | 74M | 87.8M | 98.6M | 108M | 153M | 172M | 189M | 202M | |
| Depreciation & amortization | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $7.08M | $0 | $0 | $0 | $0 | |
| EBITDA | -$8.14M | -$9.57M | -$7.47M | -$7.11M | -$6.74M | -$5.81M | -$6.6M | $292K | -$7.66M | -$8.41M | -$9.61M | -$10.1M |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1.9M | $7.6M | $1M | $0 | $0 | $0 | |
| Cost of revenue | $3K | $0 | $0 | $0 | $0 | $200K | $100K | $0 | $0 | $0 | |
| Gross profit | -$3K | $0 | $0 | $0 | $1.9M | $7.4M | $900K | $0 | $0 | $0 | |
| Research & development | $19.9M | $6.07M | $18.3M | $10.1M | $9.28M | $21.4M | $30.3M | $24M | $19.1M | $16M | |
| General & administrative | $12M | $15.1M | $12.8M | $9.92M | $9.6M | $11.3M | $12.6M | $13.9M | $12.4M | $12.3M | |
| Other operating expenses | $0 | $0 | -$3.03M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating expenses | $31.9M | $21.2M | $31.6M | $20M | $18.9M | $32.7M | $42.9M | $37.9M | $31.5M | $28.3M | |
| Operating income | -$16M | -$15.7M | -$31.6M | -$20M | -$17M | -$25.3M | -$42M | -$37.9M | -$31.5M | -$28.3M | |
| Interest income | $0 | $0 | $0 | $118K | $26K | $6K | $317K | $525K | $632K | $1.41M | |
| Interest expense | $3.51M | $462K | $266K | $118K | $0 | $0 | $0 | $0 | $0 | $0 | |
| Other non-operating income (gains on investments, FX ...) | $526K | $7.33M | -$2.81M | -$2.83M | -$208K | -$5.7M | -$10M | -$529K | -$632K | -$1.41M | |
| Total non-operating income | $5.13M | -$7.79M | $2.54M | $668K | $208K | $4.36M | $649K | $529K | $632K | $1.41M | |
| Income before tax | -$17.7M | -$23.5M | -$29M | -$19.4M | -$16.8M | -$20.9M | -$41.3M | -$37.3M | -$30.9M | -$26.9M | |
| Income tax | $243K | $253K | -$1.38M | -$81K | -$17K | -$237K | $0 | $0 | $0 | $0 | |
| Net income | -$23.5M | -$23.8M | -$27.7M | -$19.3M | -$16.8M | -$20.7M | -$41.3M | -$37.3M | -$30.9M | -$26.9M | |
| EPS (basic) | -$933.13 | -$521.91 | -$157.72 | -$10.92 | -$2.11 | -$1.34 | -$2.13 | -$1.34 | -$0.50 | -$0.25 | |
| EPS (diluted) | -$933.13 | -$521.91 | -$157.72 | -$10.92 | -$2.11 | -$1.34 | -$2.13 | -$1.34 | -$0.50 | -$0.25 | |
| Shares (basic, weighted) | 18K | 45K | 175K | 1.77M | 7.94M | 15.5M | 19.4M | 27.8M | 61.2M | 109M | |
| Shares (diluted, weighted) | 18.9K | 46.8K | 262K | 2.56M | 7.98M | 15.5M | 19.4M | 27.8M | 61.2M | 109M | |
| Depreciation & amortization | $3K | $258K | $22M | $17.2M | $282K | $1.27M | $457K | $37.9M | $31.5M | $0 | |
| EBITDA | -$16M | -$22.8M | -$6.74M | $0 | -$16.5M | -$18.3M | -$31.5M | $529K | $632K | -$26.9M |
Standardised from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics and estimates are standardised from the company's filings. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
Data as of 2026-11-21